Mavacamten Outcomes in Hypertrophic Cardiomyopathy (HCM) and the Associated Patient and Physician Experiences in the US
← catalyst calendarNCT07557498 · readout in 116 d
Sponsored by Bristol-Myers Squibb (industry) · BMY — their whole pipeline →.
Phase
—
Status
Recruiting
Study type
Observational
Enrollment
362estimated
Sites
1
Country
United Kingdom
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-01-15 | actual | When the study began enrolling |
| Primary completion | 2026-12-14 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-06-17 | estimated | The whole study's end, after follow-up |
| First posted | 2026-04-29 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-04-29 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Obstructive Hypertrophic Cardiomyopathy (oHCM)
Intervention
- Drug: Mavacamten
Primary outcomes
what the primary-completion date above is the date OFParticipant blood pressure (both systolic and diastolic)
measured Baseline
Date of diagnosis of hypertrophic cardiomyopathy
measured Baseline
Hypertrophic cardiomyopathy genetic testing results
measured Baseline
Family history of hypertrophic cardiomyopathy
measured Baseline
Family history of Sudden Cardiac Death (SCD)
measured Baseline
Participant comorbidities (cardiovascular and non-cardiovascular )
measured Baseline
Type of prior surgeries and procedures
measured Baseline and up to week 24
Participant New York Heart Association (NYHA) class category
measured Baseline, and at weeks 4, 8, 12, 24
Change in participant New York Heart Association (NYHA) class from baseline
measured Baseline, and at weeks 4, 8, 12, 24
Duration of mavacamten treatment
measured Baseline, and at weeks 4, 8, 12, 24
Number of mavacamten dose titrations
measured Baseline, and at weeks 4, 8, 12, 24
Type of mavacamten dose tritration
measured Baseline, and at weeks 4, 8, 12, 24
Clinical reason for mavacamten dose titration
measured Baseline, and at weeks 4, 8, 12, 24
Clinical reason for mavacamten treatment discontinuation
measured Baseline, and at weeks 4, 8, 12, 24
Left Ventricular Ejection Fraction (LVEF) recovery after mavacamten discontinuation if discontinued due to LVEF<50%,
measured Baseline, and at weeks 4, 8, 12, 24
Time from mavacamten discontinuation to Left Ventricular Ejection Fraction (LVEF) recovery
measured Baseline, and at weeks 4, 8, 12, 24
Clinical reason for temporary mavacamten treatment interuption
measured Baseline, and at weeks 4, 8, 12, 24
Time to temporary mavacamten treatment interruption
measured Baseline, and at weeks 4, 8, 12, 24
Left Ventricular Ejection Fraction (LVEF) recovery after mavacamten interruption if the interruption was due to LVEF<50%
measured Baseline, and at weeks 4, 8, 12, 24
Time from mavacamten treatment interruption to Left Ventricular Ejection Fraction (LVEF) recovery
measured Baseline, and at weeks 4, 8, 12, 24
Time to mavacamten treatment resumption
measured Baseline, and at weeks 4, 8, 12, 24
Type of hypertrophic cardiomyopathy (HCM) background therapy prescribed
measured Baseline, and at weeks 4, 8, 12, 24
Type of changes to hypertrophic cardiomyopathy (HCM) background therapy
measured At baseline, weeks 4, 8, 12, 24
Permalink · BMY's whole pipeline · Catalyst calendar · Every registered study · What changed